Aegerion Pharmaceuticals
About
Aegerion Pharmaceuticals engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases.
- 101 - 250
Details
- Last Funding Type
- Convertable Note
- Last Funding Money Raised
- $3.76M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2005
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases.It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia.Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 18, 2008 | Convertable Note | $3.76M | 1 | — | — | Detail |
| Nov 30, 2007 | Series B | $17.60M | 1 | — | — | Detail |
| Jun 13, 2006 | Series A | $22.50M | 1 |
Advent International
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Advent International
|
— | Convertable Note |
